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Abstract: The marine carotenoid fucoxanthin can be found in marine brown seaweeds, the 
macroalgae, and diatoms, the microalgae, and has remarkable biological properties. 
Numerous studies have shown that fucoxanthin has considerable potential and promising 
applications in human health. In this article, we review the current available scientific 
literature regarding the metabolism, safety, and bioactivities of fucoxanthin, including its 
antioxidant, anti-inflammatory, anticancer, anti-obese, antidiabetic, antiangiogenic and 
antimalarial activities, and its protective effects on the liver, blood vessels of the brain, 
bones, skin, and eyes. Although some studies have shown the bioavailability of 
fucoxanthin in brown seaweeds to be low in humans, many studies have suggested that a 
dietary combination of fucoxanthin and edible oil or lipid could increase the absorption 
rate of fucoxanthin, and thus it might be a promising marine drug. 
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1. Introduction 
Fucoxanthin is one of the most abundant carotenoids, and contributes more than 10% of the 
estimated total production of carotenoids in nature, especially in the marine environment [1]. 
Fucoxanthin is an orange-colored pigment, along with chlorophylls a and c and β-carotene, present in 
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Chromophyta  (Heterokontophyta  or Ochrophyta), including brown seaweeds (Phaeophyceae) and 
diatoms (Bacillariophyta) [2,3]. Fucoxanthin was first isolated from the marine brown seaweeds 
Fucus, Dictyota, and Laminaria by Willstätter and Page [4] in 1914. The complete structure (Figure 1) 
of fucoxanthin including chirality was determined by Englert et al. [5]. Some brown seaweeds are the 
most common edible macroalgae in South-East Asia and a few European countries [6]. Diatoms are 
unicellular planktonic microalgae and exhibit a characteristic golden-brown color due to a high amount 
of fucoxanthin that plays a major role in the light-harvesting complex of photosystems [7]. 
Figure 1. Structures of fucoxanthin and its metabolites fucoxanthinol, amarouciaxanthin A, 
and halocynthiaxanthin. 
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Fucoxanthin has been isolated for its bioactivity studies from the marine brown seaweeds   
Alaria crassifolia [8], Cladosiphon okamuranus [9], Cystoseira hakodatensis [8,10], Eisenia bicyclis [8], 
Fucus serratus [11], Fucus vesiculosus [12], Hijikia fusiformis [13,14], Ishige okamurae [15], 
Kjellmaniella crassifolia [8], Laminaria japonica [16–18], Laminaria  ochotensis [18],   
Myagropsis myagroides [19], Padina tetrastromatica [6], Petalonia binghamiae [20],   
Sargassum fulvellum [14], Sargassum heterophyllum [21], Sargassum horneri [10],   
Sargassum siliquastrum [22], and Undaria pinnatifida [10,14,23–32], and the diatoms   
Chaetoseros  sp. [33,34], Cylindrotheca closterium [35], Odontella aurita [36], and   
Phaeodactylum tricornutum [2]. 
Fucoxanthin has remarkable biological properties based on its unique molecular structure similar  
to neoxanthin, dinoxanthin, and peridinin, which is different from that of other carotenoids such as  
β-carotene and astaxanthin. Fucoxanthin has an unusual allenic bond and some oxygenic functional 
groups such as epoxy, hydroxyl, carbonyl and carboxyl moieties in its molecule (Figure 1) that 
contribute to its unique structure [2,14]. The allenic bond was found mainly in carotenoids such as 
fucoxanthin, which was the first allenic carotenoid found in brown seaweeds [1], and was responsible 
for the higher antioxidant [27]. 
This article reviews the current available scientific literature regarding the metabolism, safety, and 
bioactivities of fucoxanthin, including its antioxidant, anti-inflammatory, anticancer, anti-obese, 
antidiabetic, antiangiogenic and antimalarial activities, and its protective effects on the liver, blood 
vessels of the brain, bones, skin, and eyes. 
2. Bioavailability, Metabolism, and Safety of Fucoxanthin 
2.1. Bioavailability and Metabolism of Fucoxanthin 
Solubilization of carotenoids in mixed micelles is considered to be requirement for absorption by 
intestinal cells. Sugawara et al. [37] demonstrated that phospholipids had intense effects on carotenoid 
absorption, and the cellular absorption was dependent on the lipophilicity of carotenoids. This study 
suggested that pancreatic phospholipase A2 and lysophosphatidylcholine were crucial in modulating 
the absorption of carotenoids in the gastrointestinal tract and supported a simple diffusion mechanism 
for carotenoid assimilation by the intestinal epithelium. It was suggested that fucoxanthin was more 
readily absorbed than lutein esters in mouse intestine [38] and its metabolites were accumulated in the 
body at a higher ratio than astaxanthin [39]. 
It had been previously reported that ingested fucoxanthin was totally deacetylated in the instestinal 
lumen and transported via blood in White leghorn laying hens fed the brown seaweed F. serratus, and 
thus fucoxanthinol was present as one of the main carotenoids in egg yolk [11]. Sugawara et al. [40] 
showed that fucoxanthin was hydrolyzed to fucoxanthinol during the uptake by differentiated Caco-2 
cells, a tissue culture model for studying the absorption of dietary compounds by human intestinal 
epithelium. This study also showed fucoxanthinol appeared in mouse plasma after ingestion of 
fucoxanthin, indicating that dietary fucoxanthin was deacetylated into fucoxanthinol in the intestinal 
tract by lipase and esterase from the pancreas or in intestinal cells, and incorporated as fucoxanthinol Mar. Drugs 2011, 9  
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from the digestive tract into the blood circulation system in mammals. Therefore, the bioavailability of 
fucoxanthinol is higher than that of fucoxanthin in the body [41]. 
Asai et al. [42] investigated further biotransformation of fucoxanthinol in ICR mice and HepG2 
cells, and revealed that an unknown metabolite had been previously found in marine tunicate 
Amaroucium pliciferum, and thus was identified as amarouciaxanthin A (Figure 1). The bioconversion 
of fucoxanthinol into amarouciaxanthin A through dehydrogenation/isomerization was principally 
shown in liver microsomes, and fucoxanthinol supplemented to culture medium via HepG2 cells   
was also converted into amarouciaxanthin A. Therefore, it was suggested that fucoxanthin was 
converted to fucoxanthinol in the gastrointestinal tract and was then metabolized to amarouciaxanthin 
A in the liver [6,10,39,42–44], and no fucoxanthin was detected in plasma and liver [42,44]. 
Hashimoto et al. [39] found that fucoxanthinol and amarouciaxanthin A were detectable in plasma, 
erythrocytes, the liver, lungs, kidney, heart, spleen, and adipose tissue in ICR mice fed 160 nmol 
fucoxanthin, whereas no fucoxanthin was detected in these tissues or in the blood.  
However, the daily oral administration of fucoxanthin for 1 week showed that a small amount of 
fucoxanthin was not metabolized and was detectable in the liver, lung, kidney, heart, spleen, and 
adipose tissue of the mice [39]. The percentage of fucoxanthin, fucoxanthinol, and amarouciaxanthin A 
to the sum of all of these in the adipose tissue was 13, 32, and 55%, respectively, while the percentage 
in the other tissues was 1−11, 63−76 and 20−26%, respectively [39], indicating that amarouciaxanthin 
A accumulated preferentially in the adipose tissue [10,38,39], while fucoxanthinol accumulated mainly 
in the liver, lungs, kidney, heart, and spleen [39]. Yonekura et al. [38] showed that fucoxanthinol and 
amarouciaxanthin A accumulated mainly in adipose tissues (3.13–3.64 μmol/kg), in which the contents 
were 2.2- to 2.6-fold of that in plasma, liver, and kidney (1.29–1.80 μmol/kg) in ICR mice fed 128 nmol 
fucoxanthin daily for 14 days.  
Further transformation of amarouciaxanthin A to more polar metabolites might be taking place in 
ICR mice [38]. Sangeetha et al. [6] reported in detail on various metabolites of fucoxanthin besides the 
major metabolites fucoxanthinol and amarouciaxanthin A in rats, proposed a possible metabolic 
pathway of fucoxanthin in the plasma and liver of rats, and speculated that these metabolites might be 
formed as a result of enzymatic reactions such as isomerization, dehydrogenation, deacetylation, 
oxidation, and demethylation. 
In addition, in marine animals such as oysters and clams [45–47], fucoxanthinol was further 
metabolized into halocynthiaxanthin (Figure 1), which was first isolated from sea squirt   
Halocynthia roretzi [48,49]. 
In a human study, Asai et al. [28] determined the plasma concentrations of fucoxanthin metabolites 
before and after 1-week dietary interventions with U. pinnatifida to estimate the intestinal absorption 
of fucoxanthin in five healthy volunteers. The results showed that the plasma concentration of 
fucoxanthinol was low (0.8 nmol/L) after 1 week of uptake (6.1 mg fucoxanthin/day), and no 
fucoxanthin and amarouciaxanthin A was detected in the plasma, and it was possible that some 
components (e.g., dietary fibre) in algal matrix inhibited the intestinal absorption of fucoxanthin. 
It has been suggested that dietary combination of fucoxanthin and edible oil or lipid could increase 
the absorption rate of fucoxanthin in KK-Ay mice [32,50,51] and in obese premenopausal women [52].  Mar. Drugs 2011, 9  
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2.2. Safety of Fucoxanthin 
Fucoxanthin and fucoxanthinol had few adverse effects on normal and uninfected cells both in vitro 
and in vivo [53,54]. Zaragozá et al. [12] studied the toxicity of extracts from F. vesiculosus in mice and 
rats, and indicated that even at the dose of 750 mg/kg daily for 4 weeks, no any relevant signs of toxicity 
occurred. Kadekaru et al. [55] conducted a toxicity study on the repeated oral dosing of fucoxanthin 
(95% purity) to rats for 28 days, and revealed that fucoxanthin did not show obvious toxicity.  
Beppu et al. [3] conducted a single dose toxicity study at doses of 1000 and 2000 mg/kg and a 
repeated oral dose toxicity study at doses of 500 and 1000 mg/kg for 30 days on purified fucoxanthin 
(93% purity) in ICR mice. The results showed that no mortality and no abnormalities in gross 
appearance were found in both studies, and no abnormal changes in liver, kidney, spleen, and gonadal 
tissues induced by fucoxanthin in the histological observations of the repeated doses study. 
Subsequently, Beppu et al. [56] indicated that fucoxanthin had no genotoxic/mutagenic effect on the 
bone marrow cells of mice. Iio et al. [33,34] investigated the subchronic toxicity of fucoxanthin in rats 
and genotoxicity in mice. In the single oral dose study, no mortality and no change were observed. The 
50% lethal dose of fucoxanthin was more than 2000 mg/kg body weight. In the 13-week oral dose 
study, the no-observed-adverse-effect level of fucoxanthin was 200 mg/kg body weight under the 
tested subchronic dose condition. These studies suggested that fucoxanthin was a safe compound and 
did not exhibit toxicity and mutagenicity under these experimental conditions [3,34,56]. 
However, some carotenoids may have ability to increase circulating cholesterol level in rodents as  
a common feature [3]. Although fucoxanthin markedly elevated plasma high-density lipoprotein 
cholesterol level [3,55,57], total cholesterol level in the blood significantly increased to the same degree 
while the dose of fucoxanthin was 50 mg/kg daily for 28 days in Crl:CD (SD) rat and 1000 mg/kg daily 
for 30 days in ICR mice [3,55]. To further ascertain the safety of fucoxanthin, the mechanism by 
which fucoxanthin induces hypercholesterolemia and species differences should be elucidated. 
3. Potential Health-Promoting Effects of Fucoxanthin 
3.1. Antioxidant Activity 
Antioxidant activity is one of the important characteristics of carotenoids, and many of their 
biological effects are related to the ability to scavenge reactive oxygen species, which is one of the 
factors for their disease preventing effects [27]. Earlier studies had indicated that fucoxanthin was also 
an effective radical scavenger [2,14]. The chemically generated radicals used to evaluate the antioxidant 
activity of fucoxanthin include DPPH (1,1-diphenyl-2-picrylhydrazyl), 12-DS (12-doxyl-stearic acid), 
NB-L (the radical adduct of nitrosobenzene with linolenic acid radical), AAPH (2,2′-azo-bis- 
(2-amidinopropane) dihydrochloride), ABTS (2,2′-azinobis-3-ethylbenzothiazoline-6-sulphonate), and 
ABAP (2,2′-azo-bis-2-amidinopropane) [8,12,13,27]. 
It has been reported that the extracts of H. fusiformis,  C. okamuranus,  U. pinnatifida, and   
S. fulvellum showed a strong DPPH radical scavenging activity [9,14]. Recently, Airanthi et al. [8] 
showed that the methanol extract of C. hakodatensis was a good source for antioxidants and the high 
antioxidant activity was based not only on the high content of phenolics, but also on the presence of 
fucoxanthin, demonstrating the synergy in the antioxidant activity of phenolics and fucoxanthin. Mar. Drugs 2011, 9  
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Although two extracts from F. vesiculosus containing 28.8% polyphenols or 18% polyphenols and 
0.0012% fucoxanthin, respectively, exhibited antioxidant activity in noncellular systems (O2
•−, DPPH, 
ABTS, and ABAP) and in activated RAW 264.7 macrophages, as well as in ex vivo assays in plasma 
and erythrocytes, after the 4-week treatment in rats, only extract containing fucoxanthin showed an 
antioxidant activity ex vivo through preventing oxidant formation, scavenging superoxide anion (O2
•−), 
and reducing active intermediates [12].  
It was shown that fucoxanthin scavenged organic free radicals 12-DS, DPPH, and NB-L with the 
inhibitions of 66% (incubation for 12 h), 28% (1 h), and 57% (12 h), respectively, in the electron spin 
resonance signal intensities [13]. Fucoxanthin could effectively inhibit intracellular reactive oxygen 
species formation, DNA damage, and apoptosis induced by H2O2, possibly due to the ability of 
fucoxanthin to increase catalase [22]. 
Sachindra et al. [27] assessed the antioxidant activities of fucoxanthin and its two metabolites, 
fucoxanthinol and halocynthiaxanthin, in vitro with respect to radical scavenging (DPPH, ABTS, 
hydroxyl radical, and superoxide radical) and singlet oxygen quenching abilities, and suggested that 
fucoxanthin and fucoxanthinol exhibited antioxidant activities higher or similar to that of α-tocopherol, 
and halocynthiaxanthin showed comparatively lower antioxidant activities. The hydroxyl radical 
scavenging activity of fucoxanthin was 7.9, 16.3, and 13.5 times higher than that by fucoxanthinol, 
halocynthiaxanthin, and α-tocopherol, respectively, but singlet oxygen quenching ability of fucoxanthin 
was lower than that of β-carotene. Although halocynthiaxanthin showed very poor scavenging activity, 
of 19 carotenoids including halocynthiaxanthin, fucoxanthinol, astaxanthin, canthaxanthin, lutein, and 
β-carotene, halocynthiaxanthin showed the highest suppressive effect on superoxide anion (O2
•−) and 
nitric oxide (NO) generation from differentiated human promyelocytic HL-60 cells and mouse 
macrophage RAW 264.7 cells, respectively [45]. 
Burton and Ingold [58] previously pointed out that β-carotene exhibited good radical-trapping 
antioxidant activity only at partial pressures of oxygen significantly less than the pressure of oxygen in 
normal air, which is found in most tissues under physiological conditions. Nomura et al. [2] found that, 
under anoxic conditions, fucoxanthin equimolarly reacted with DPPH as radical quencher, whereas  
β-carotene, β-cryptoxanthin, zeaxanthin, licopene, and lutein scarcely reacted with DPPH and had 
practically no quenching activities, suggesting that fucoxanthin was more reactive to radicals than other 
carotenoids under anoxic conditions. However, under aerobic conditions, only a part of fucoxanthin 
consumed DPPH and fucoxanthin was relatively less sensitive than β-carotene. Under a high oxygen 
pressure, e.g., 100 kPa, fucoxanthin had much less antioxidant activity than α-tocopherol for the 
oxidation of methyl linoleate in heptanol in the presence of 2,2′-azo-bis-iso-butyronitrile at 60 °C [59].  
Sangeetha et al. [44,60] compared the effects of fucoxanthin and β-carotene on oxidative stress 
indicators (catalase, glutathione transferase, and Na
+K
+-ATPase) and the possible role in suppressing 
lipid peroxidation resulting from retinol deficiency in rats. The results showed that fucoxanthin and  
β-carotene protected cell membrane by decreasing Na
+K
+-ATPase activity and increasing the activities 
of catalase and glutathione transferase at the tissue and microsomal level affected by retinol deficiency 
possibly due to its antioxidant activity, thus protecting membranes against lipid peroxidation caused by 
retinol deficiency. The results also showed that fucoxanthin had greater potential than β-carotene and 
was somewhat more effective than retinol in reducing lipid peroxidation in plasma and liver resulting 
from retinol deficiency. Li et al. [61] showed that vitamin D2 was oxidized by singlet oxygen in the Mar. Drugs 2011, 9  
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presence of riboflavin, light, and oxygen in a model system, and fucoxanthin and β-carotene could 
minimize the oxidation of vitamin D2 by quenching singlet oxygen. 
The major structural differences in fucoxanthin and other carotenoids are the presence of an unusual 
allenic carbon (C-7′), 5,6-monoepoxide, two hydroxyl groups, a carbonyl group, and an acetyl group in 
the terminal ring of fucoxanthin [2,14]. The allenic bond was responsible for the higher antioxidant 
activity of fucoxanthin [27]. In addition, fucoxanthin has six oxygen atoms, and thus might be more 
sensitive to radicals, especially under anoxic conditions. It has been suggested that the antioxidant 
activity of carotenoids is correlated with the presence of intramolecular oxygen atoms [2].  
It is worth mentioning that fucoxanthin also contains an α,β-unsaturated carbonyl group, and may 
function as a Michael acceptor which can react with important proteins such as Keap 1 in the Nrf2 
system [62]. Liu et al. [62] recently showed that fucoxanthin enhanced HO-1 and NQO1 expression in 
murine hepatic BNL CL.2 cells through activation of the Nrf2/ARE system, and suggested that 
fucoxanthin might exert its antioxidant activity, at least partly, through its pro-oxidant actions. 
3.2. Anti-Inflammatory Effects 
Inflammatory response, a self-defensive reaction against various pathogenic stimuli, is characterized 
by attracting large amounts of leukocytes (neutrophiles, monocytes-macrophages, and mast cells) to 
the inflamed area, in which these inflammatory cells are triggered by inflammation mediators and 
generate superoxide anion and nitric oxide radicals, and may become a harmful self-damaging   
process [12,63]. Anti-inflammatory agents should reduce the inflammatory response by suppressing 
the productions of inflammatory cytokines such as tumor necrosis factor-α, interleukin-1β, and 
interleukin-6, and inflammatory mediators, including nitric oxide and prostaglandin E2 synthesized by 
inducible nitric oxide synthase and cyclooxygenase [64].  
Heo et al. [22] and Kim et al. [65] authenticated the inhibitory effects of fucoxanthin on inflammatory 
cytokines and mediators in lipopolysaccharide-stimulated RAW 264.7 macrophages. These results 
showed that fucoxanthin inhibited the inducible nitric oxide synthase and cyclooxygenase 2 protein 
expressions, and reduced the levels of nitric oxide, prostaglandin E2, tumor necrosis factor-α, 
interleukin-1β, and interleukin-6 through the inhibition of nuclear factor-κB activation and the 
phosphorylation of mitogen-activated protein kinases [22,65]. 
Sakai et al. [66] indicated that fucoxanthin suppressed the degranulation of mast cells by inhibiting 
antigen-induced aggregation of high affinity IgE receptor followed by activation of the degranulating 
signals of mast cells, which played important roles in inflammation and immediate-type allergic reactions. 
Recently, Sakai et al. [67] evaluated the effect of carotenoids on dinitrofluorobenzene-induced contact 
hypersensitivity in mice to elucidate their effect on mast cell degranulation in vivo, and showed that 
fucoxanthin significantly inhibited ear swelling and reduced the levels of tumor necrosis factor-α and 
histamine, suggesting that fucoxanthin exerted an anti-inflammatory effect by suppressing mast cell 
degranulation in vivo. 
Khan et al. [29,68] investigated the anti-inflammatory activity of methanol extract of U. pinnatifida 
against mouse ear edema and erythema induced by phorbol myristate acetate. The results showed that 
the extract suppressed edema and erythema with relative inhibition of 85 and 78%, respectively [68], 
and inhibited erythema by 50% when applied within 1 h before or 15 min after application of phorbol Mar. Drugs 2011, 9  
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myristate acetate [29]. In addition, the extract suppressed the acetic acid-induced writhing response in 
the analgesic test, and also demonstrated antipyretic activity in yeast-induced hyperthermic mice [69].  
3.3. Anticancer Activity 
Apoptosis induction has been suggested to be the biochemical mechanism by which fucoxanthin 
exerted an inhibitory effect on tumor cells [23,25,31,70,71]. The apoptosis-inducing effect   
of fucoxanthin on human promyelocytic leukemia HL-60 cell line has been investigated by   
Hosokawa et al. [23], who found that fucoxanthin exhibited strong antiproliferative activity and could 
induce apoptosis of HL-60 cells. In HL-60 cells, fucoxanthin caused cleavages of procaspase-3 and 
poly-ADP-ribose polymerase, and apoptosis induction by fucoxanthin was mediated through 
mitochondrial membrane permeabilization and caspase-9 and caspase-3 activation [72]. Kim et al. [15] 
showed that fucoxanthin induced reactive oxygen species generation, inactivated the Bcl-xL signaling 
pathway, induced caspase-3, -7, and poly-ADP-ribose polymerase cleavage, and thus triggered the 
apoptosis of HL-60 cells, indicating that the generation of reactive oxygen species was a critical target 
in fucoxanthin-induced apoptosis in HL-60 cells. 
It had been reported that β-carotene did not show an apoptosis-inducing effect on HL-60 cells, 
indicating that the carotenoid structure might be crucial for inducing apoptosis [23]. Recently,   
Ganesan  et al. [73] showed that fucoxanthin, astaxanthin, siphonaxanthin, neoxanthin, and 
violaxanthin had significant cytotoxic effects against cultured HL-60 cells and the inhibitory effect of 
fucoxanthin on the viability of HL-60 cells was remarkable compared with astaxanthin, β-carotene, 
zeaxanthin, lutein, etc. Both halocynthiaxanthin and fucoxanthinol showed remarkable induction of 
apoptosis in HL-60 cells, MCF-7 breast cancer cells, and Caco-2 colon cancer cells, and the 
antiproliferative and apoptosis-inducing effects of halocynthiaxanthin and fucoxanthinol on these cells 
were significantly greater than those of fucoxanthin, possibly at least partly, related to the hydroxyl 
group in halocynthiaxanthin and fucoxanthinol [49]. Both fucoxanthinol and amarouciaxanthin A also 
reduced the viability of PC-3 human prostate cancer cells, and the 50% inhibitory concentrations of 
fucoxanthin, fucoxanthinol, and amarouciaxanthin A on the proliferation of PC-3 cells were 3.0, 2.0, 
and 4.6 μM, respectively, indicating that the 5,6-epoxide in fucoxanthin and fucoxanthinol played 
important roles in cytotoxicity, and other mechanisms might be also involved in the antiproliferative 
effect of epoxycarotenoids on PC-3 cells [42]. 
Adult T-cell leukemia is an incurable malignancy of mature CD4
+ T cells caused by human T-cell 
leukemia virus type 1. Ishikawa et al. [53] assayed the antiproliferative effects of some carotenoids 
such as fucoxanthin, fucoxanthinol, β-carotene and astaxanthin, and found that both fucoxanthin   
and fucoxanthinol had remarkable antiproliferative effects on human T-cell leukemia virus type   
1-infected T-cell lines and adult T-cell leukemia cells in vitro, and β-carotene and astaxanthin had mild 
inhibitory effects. 
The exposure of human non-small-cell bronchopulmonary carcinoma line NSCLC-N6 and human 
lung epithelial cell line A549 to fucoxanthin distinctly induced morphological change such as rounding 
up, reduction of cell volume, chromatin condensation, nuclei fragmentation, and formation of 
apoptotic bodies for the two bronchopulmonary cells lines, and suggested that fucoxanthin could 
trigger the terminal differentiation of cancerous cells in vitro [36]. Mar. Drugs 2011, 9  
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It was reported that fucoxanthin reduced the viability of human colon cancer cell lines Caco-2,   
HT-29, and DLD-1 cells (Caco-2 > DLD-1 > HT-29) and induced apoptosis in a dose- and   
time-dependent manner, while astaxanthin and β-carotene were not found to change the viability of 
Caco-2 cells. The decreased expression level of Bcl-2 protein might contribute to fucoxanthin-induced 
apoptosis in Caco-2 cells [25]. Kotake-Nara et al. [71] evaluated the effects of fucoxanthin and 
neoxanthin on the viability of human colorectal carcinoma Caco-2, human colorectal adenocarcinoma 
HCT116 cell lines, mouse melanoma B16, human normal embryonic lung fibroblast MRC-5, and 
human male umbilical cord fibroblast HUC-Fm cell lines. The results showed that fucoxanthin and 
neoxanthin had nearly the same actions on the cultured cells and were more effective in reducing the 
viability of HCT116 cancer cells than that of the other cancer and normal cell lines, while lycopene 
was found to be less effective. Das et al. [74] indicated that fucoxanthin inhibited the proliferation of 
human colon cancer cell lines WiDr and HCT116 cells by inducing cell cycle arrest at the G0/G1 
phase through up-regulating the cyclin-dependent kinase inhibitory protein p21
WAF1/Cip1 and 
retinoblastoma protein (pRb). 
Kotake-Nara  et al. [70] showed that fucoxanthin significantly reduced the viability of three   
human prostate cancer cell lines PC-3, DU 145 and LNCaP to 14.9%, 5.0%, and 9.8%, respectively, 
through apoptosis induction in these cancer cells. The succeeding study demonstrated that fucoxanthin 
decreased the levels of Bax and Bcl-2 proteins, and induced apoptosis in PC-3 cells through caspase-3 
activation [71,75]. Satomi and Nishino [76] showed that fucoxanthin induced cell cycle arrest at the 
G1 phase and GADD45A expression, and inhibited the growth of DU145 cells. The results suggested 
that GADD45A and Pim-1 protooncogene might be important genes associated with the action of 
fucoxanthin, and GADD45A might be involved in fucoxanthin-induced G1 arrest. In the subsequent 
study, Satomi and Nishino [77] showed that several MAPKs modulated the induction of GADD45 and 
G1 arrest, and positive regulation by SAPK/JNK was involved in GADD45A induction and G1 arrest 
by fucoxanthin, indicating that GADD45A was closely related with the G1 arrest induced by 
fucoxanthin, and MAPK pathways were implicated in fucoxanthin-induced GADD45A expression and 
G1 cell cycle arrest in tumor cells depending on the cell type. 
Satomi and Nishino [76] previously showed that fucoxanthin inhibited the growth of human 
hepatocellular carcinoma HepG2 cells. In the subsequent study, Satomi and Nishino [77] investigated 
the role of MAPKs in the induction of G1 arrest and GADD45 expression by fucoxanthin in HepG2 
cells, and showed that the inhibitions of p38 MAPK and ERK1/2 MAPK enhanced the induction of 
GADD45A and GADD45B expressions, respectively, and GADD45A was an important factor in the 
induction of G1 arrest by fucoxanthin in HepG2 cells. The molecular mechanisms of fucoxanthin 
against hepatocellular carcinoma using HepG2 cells had been studied by Das et al. [16], who found 
that the growth-inhibitory effect of fucoxanthin on the cancer cells was chiefly due to an arrest in the 
G0/G1 phase of the cell cycle, and no apoptosis was observed, indicating that fucoxanthin possessed 
cytostatic rather than cytocidal activity in HepG2 cells. This study suggested that both the proteolysis 
and transcriptional suppression might be responsible for the decreasing levels of cyclin Ds and the 
suppression of cyclin D/cdk4 activity in fucoxanthin-treated HepG2 cells and might be related to the 
antitumor activity. Liu et al. [30] indicated that fucoxanthin effectively inhibited the proliferation of 
human hepatoma SK-Hep-1 cells but facilitated the growth of murine embryonic hepatic BNL CL.2 
cells. The study found that fucoxanthin significantly increased protein and mRNA expressions of Mar. Drugs 2011, 9  
 
 
1815
connexin 43 and connexin 32 in SK-Hep-1 cells, and thus enhanced gap junctional intercellular 
communication of SK-Hep-1 cells, which might be responsible for the increase of the intracellular 
calcium level, leading to cell cycle arrest at G0/G1 phase, DNA fragmentation, and apoptosis of   
SK-Hep-1 cells. 
Recently, the effects of fucoxanthin on human gastric adenocarcinoma MGC-803 cells were 
investigated by Yu et al. [78], who found that fucoxanthin induced cell cycle arrest in G2/M phase  
and apoptosis of MGC-803 cells, and down-regulated the expressions of CyclinB1 and survivin in 
MGC-803 cells. The study also showed that fucoxanthin might reduce CyclinB1 expression through 
JAK/STAT signal pathway, and thus inhibit proliferation of MGC-803 cells. 
Bladder cancer is not only a serious malignancy but also the most expensive cancer to survey and 
treat. Zhang et al. [17] showed that fucoxanthin exhibited remarkable antiproliferative effects on 
human urinary bladder cancer EJ-1 cells and reduced the viability of EJ-1 cells by inducing apoptosis, 
which was characterized by morphological changes, DNA ladder, and increased percentage of 
hypodiploid cells, and activating caspase-3 activity with a maximum ratio of apoptotic cells of >93% 
with 20 μM fucoxanthin. 
Primary effusion lymphoma is a very aggressive type of non-Hodgkin’s lymphoma infected by 
human herpesvirus 8. It was found that fucoxanthin and fucoxanthinol decreased cell viability in 
primary effusion lymphoma BCBL-1 and TY-1 cells. Fucoxanthin and fucoxanthinol induced cell 
cycle arrest during G1 phase and caspase-dependent apoptosis, inhibited the activation of nuclear 
factor-κB, activator protein-1, and phosphatidylinositol 3-kinase/Akt pathways, and down-regulated 
anti-apoptotic proteins and cell cycle regulators in primary effusion lymphoma cells. In addition, 
fucoxanthin reduced the growth of primary effusion lymphoma cells in the xenografted mice, 
suggesting that fucoxanthin could be potentially effective for the treatment of primary effusion 
lymphoma [54]. 
An earlier study indicated that fucoxanthin inhibitd the growth of the human neuroblastoma   
GOTO cells by causing the arrest in the G0–G1 phase of cell cycle and decreasing N-myc gene 
expression [79]. Subsequently, Nishino et al. [48] found that halocynthiaxanthin showed a more potent 
inhibitory effect on the growth of human neuroblastoma GOTO cells, and also inhibited the growth of 
other human malignant tumor cells. 
The antiproliferative effect of fucoxanthin is dependent on its isomeric structure. Nakazawa et al. [31] 
found that the antiproliferative activity of 13-cis and 13′-cis fucoxanthin was significantly higher than 
that of the all-trans or 9′-cis isomeric forms on the growth of cancer cells. In addition,   
13′-cis fucoxanthin had greatest inhibitory effect on the growth of HL-60 cells, followed by 13-cis 
isomer and all-trans or 9′-cis isomers. It was suggested that the stronger antiproliferative and inhibitory 
effect of cis-fucoxanthin might be due to the steric hindrances offered by their structure. 
In animal experiment, fucoxanthin significantly inhibited the formation and development of   
aberrant crypt foci, a preneoplastic marker for colon cancer, induced by azoxymethane [80] and   
1,2-dimethylhydrazine dihydrochloride [81] in mice. Fucoxanthin had been proven to suppress 
spontaneous liver tumorigenesis in C3H/He male mice and showed antitumor-promoting activity   
in a two-stage carcinogenesis experiment in the skin of ICR mice, initiated with   
7,12-dimethylbenz[a]anthracene and promoted with 12-O-teradecanoylphorbol-13-acetate and Mar. Drugs 2011, 9  
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mezerein [13]. In addition, fucoxanthin was reported to inhibit duodenal carcinogenesis induced by  
N-ethyl-N′-nitro-N-nitrosoguanidine in mice [82]. 
Although the antitumor effects of fucoxanthin are known, the precise mechanism of action has yet 
to be elucidated [76]. The anticancer activity of fucoxanthin was partly based on the regulative effect 
of fucoxanthin on biomolecules related to cell cycle and apoptosis [83]. In addition, fucoxanthin was 
found to be able to selectively inhibit the mammalian DNA polymerase activities, especially 
replicative DNA polymerases (i.e., pol α, δ, and ε), and thus had anti-neoplastic activity [20]. Further 
investigations are needed to assess the details of the molecular mechanisms of fucoxanthin against 
different types of cancer cells with animal models [83].  
3.4. Anti-Obese Effect 
An excessive accumulation of fat in the body and white adipose tissue causes obesity and a 
disturbance of cytokine secretion from adipose tissue, and thus results in an increased risk of   
many serious diseases such as type II diabetes, hyperlipidemia, hypertension, and cardiovascular 
disease [26,50,84]. 
Maeda et al. [26] firstly reported that lipids from U. pinnatifida reduced abdominal white adipose 
tissue weights in Wistar rats and KK-Ay mice. Miyata et al. [18] showed that L.  japonica and   
L. ochotensis inhibited fat absorption, decreased the serum triglyceride level in SD rats, and had an 
anti-obesity effect on ddY mice induced by a high-fat diet. It was suggested that fucoxanthin was an 
active component for the antiobesity effect [26]. Many studies have shown that fucoxanthin, even with 
a 0.02% dose [85], significantly lowered body weight [43,86–88], body fat accumulation [89], visceral 
fat-pads weights [85,87], white adipose tissue weight gain [50,88–90], and the size of adipocyte [85] in 
diabetic/obese KK-Ay mice, high-fat diet-induced obese C57BL/6N mice or C57BL/6J mice, and 
increased brown adipose tissue weight in KK-Ay mice [50]. However, fucoxanthin did not affect white 
adipose tissue weight gain in lean C57BL/6J mice [90]. It was found that fucoxanthin significantly 
reduced plasma and hepatic triglyceride concentrations and the activities of adipocytic fatty acid 
synthesis, hepatic fatty acid and triglyceride synthesis, and cholesterol-regulating enzymes, and 
significantly increased the concentrations of plasma high-density lipoprotein-cholesterol, fecal 
triglyceride and cholesterol, as well as fatty acid oxidation enzyme activity in epididymal white 
adipose tissue of mice, indicating that fucoxanthin ameliorated the plasma and hepatic lipid profile, 
fecal lipids and body fat mass, hepatic cholesterol metabolism, fatty acid synthesis, and lipid 
absorption [57,88]. Moreover, fucoxanthin significantly lowered mRNA expression of proliferators 
activated receptor γ and the activity of hepatic phosphatidate phosphohydrolase, and significantly 
increased the mRNA expressions of β-oxidation-related acyl-coA oxidase 1, palmitoyl and 
proliferators activated receptor α [57]. In addition, fucoxanthin and fucoxanthinol inhibited both 
lymphatic triglyceride absorption and the increase of triglyceride concentration in systemic blood, 
likely due to their inhibitory effects on lipase activity in the gastrointestinal lumen [91].  
The potential anti-obesity effect might be mediated by improving plasma adipokine level   
(e.g., lowered leptin level and elevated adiponectin level), down-regulating various lipogenic enzyme 
activities and fat production, up-regulating fatty acid β-oxidation activity and uncoupling protein gene 
expressions in visceral adipose tissues, suggesting that fucoxanthin might act as a regulator of lipid Mar. Drugs 2011, 9  
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metabolism in fat tissues [87]. Mitochondrial uncoupling protein 1, usually expressed only in brown 
adipose tissue that occurs little in adult humans, is a key molecule for metabolic thermogenesis to avoid 
an excess of fat accumulation [26]. Many studies suggested that the antiobesity effect of fucoxanthin was 
due to oxidation of fatty acids, heat production, and energy dissipation through upregulating the 
expression of uncoupling protein 1 in the white adipose tissue [26,50,51,86,88,92], and thus inducing 
the decrease in abdominal fat in mice [86]. Recently, Miyashita et al. [83] reported that fucoxanthin 
promoted mRNA expression of β3-adrenergic receptor in white adipose tissue of obese mice, which was 
responsible for lipolysis and thermogenesis. The regulatory effect of fucoxanthin on peroxisome 
proliferator-activated receptor γ expression in adipose tissue was an important modulator for uncoupling 
protein 1 expression. Leptin is mainly produced in adipocyte and controls body weight and fat weight by 
regulating the food intake and energy expenditure. Fucoxanthin remarkably reduced leptin mRNA in 
white adipose tissue and the level of plasma leptin in KK-Ay mice [50] and high fat diet-induced obese 
C57BL/6J mice [85,89]. The lower leptin level might reflect the decrease in the size of white adipose 
tissue induced by fucoxanthin [50]. In addition, Sugawara et al. [93] found that fucoxanthin had 
significant antiangiogenic activity, which was also responsible for its anti-obesity effect. 
Maeda  et al. [84] showed that fucoxanthin and fucoxanthinol inhibited intercellular lipid 
accumulation and decreased glycerol-3-phosphate dehydrogenase activity during adipocyte 
differentiation of 3T3-L1 cells. The suppressive effect of fucoxanthinol on the differentiation of murine 
3T3-L1 preadipocytes to adipocytes was stronger than that of fucoxanthin [84], and the suppressive 
effect of amarouciaxanthin A, a dominant metabolite of fucoxanthin in white adipose tissue, was stronger 
than that of fucoxanthinol [94]. Amarouciaxanthin A markedly down-regulated the mRNA expressions 
of adipocyte fatty acid-binding protein, lipoprotein lipase, and glucose-transporter 4 in 3T3-L1 cells [94]. 
Kang et al. [95] found that that fucoxanthin inhibited 3T3-L1 adipocyte differentiation at intermediate 
(days 2−4) and late stages (days 4−7), whereas it enhanced 3T3-L1 adipocyte differentiation at an 
early stage (days 0−2) by modulating the expression of key adipogenic transcriptional regulators such 
as peroxisome proliferator-activated receptor γ, CCAAT/enhancer-binding protein α, and sterol 
regulatory element-binding protein 1c, and inhibited glucose uptake by suppressing the 
phosphorylation of insulin receptor substrate 1 in mature 3T3-L1 adipocytes, suggesting that 
fucoxanthin exerted anti-obesity effect by inhibiting the expression of key transcriptional regulators at 
intermediate and late stages and glucose uptake in mature adipocytes. Noticeably, some non-allenic 
carotenoids, such as lutein, lutein epoxide, α-carotene, and β-carotene 5,6-epoxide, were found to not 
exhibit the suppressive effect on adipocyte differentiation in 3T3-L1 cells, indicating that the allene 
bond of fucoxanthin and its metabolites might be important for the inhibition [83,92,94,96]. 
Maeda et al. showed that, although no significant uncoupling protein 1 expression in the white 
adipose tissue of KK-Ay mice fed fish oil [50] or medium-chain triacylglycerols [51] was found, the 
anti-obesity effect of fucoxanthin was increased by dissolving fucoxanthin in fish oil or medium-chain 
triacylglycerols, indicating the combination of fucoxanthin and lipids is more effective for attenuating 
the weight gain of the white adipose tissue than feeding with fucoxanthin alone, and suggesting that 
the presence of lipids can increase the absorption rate of fucoxanthin in KK-Ay mice [50,51]. 
Recently, Okada et al. [32] developed a lipid delivery system, and suggested that incorporation of  
U. pinnatifida lipid into phospholipid by means of capsulation might lead to an additive increase in the 
antiobesity effect of fucoxanthin on KK-Ay mice. Mar. Drugs 2011, 9  
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In a 16-week clinical trial, Abidov et al. [52] investigated the effects of orally administered the 
mixture (Xanthigen) of fucoxanthin and pomegranate seed oil on body weight, body fat, liver lipids, 
blood biochemistry, and resting energy expenditure in obese, non-diabetic premenopausal women 
diagnosed with non-alcoholic fatty liver disease or presenting with normal liver fat. The results showed 
that Xanthigen reduced body weight (from 94.1 ± 2.1 and 94.5 ± 2.1 to 87.2 ± 3.7 and 88.2 ± 1.9 kg 
for volunteers with fatty liver and normal liver, respectively), body fat (from 42.3 ± 2.2 and 43.3 ± 2.9 
to 37.9 ± 2.9 and 38.1 ± 3.2 kg, respectively), and liver fat content (from 15.3 ± 4.1 and 5.1 ± 1.5 to  
9.4 ± 3.1 and 3.4 ± 1.8%, respectively), improved liver function tests in obese non-diabetic women, 
and increased resting energy expenditure. 
3.5. Antidiabetic Activity 
Maeda et al. [50] found that fucoxanthin markedly decreased the blood glucose and plasma insulin 
levels, as well as water intake in diabetic/obese KK-Ay mice. It was suggested that fucoxanthin 
improved insulin resistance and decreased blood glucose level, at least in part, through downregulating 
adipokines such as tumor necrosis factor-α, monocyte chemoattractant protein-1, interleukin-6, and 
plasminogen activator inhibitor-1 via downregulating their mRNA expression by directly acting on 
adipocytes and macrophages in white adipose tissue and up-regulation of glucose transporter 4 in 
skeletal muscle in KK-Ay mice [50,83,89,90,92].  
Hosokawa et al. [90] demonstrated that fucoxanthin attenuated hyperglycemia in KK-Ay mice, but 
did not affect blood glucose levels in lean C57BL/6J mice. However, a high-fat feeding could prompt 
obesity, hyperinsulinemia, high blood glucose, insulin resistance, and non-alcoholic fatty liver disease 
in C57BL/6J mice [85]. Maeda et al. [89] and Park et al. [85] showed that fucoxanthin significantly 
lowered the fasting blood glucose concentration, the plasma insulin level, and the insulin resistance 
index in diet-induced obese mice. Fucoxanthin might improve altera–tions in lipid metabolism   
and insulin resistance induced by a high fat diet, at least in part, through reducing visceral fat   
mass, hyperinsulinemia, hepatic glucose production, and hepatic lipogenesis, and altering hepatic 
glucose-regulating enzymes activities [85]. Moreover, Woo et al. [57] demonstrated that fucoxanthin 
significantly reduced the blood glucose, hemoglobin A1c, plasma insulin, and resistin levels, and no 
change was found in the plasma glucagon concentration in high-fat diet fed C57BL/6N mice, 
indicating that the reduction in the insulin/glucagon ratio could be in part responsible to lowering 
blood glucose concentration by fucoxanthin. 
3.6. Hepatoprotective Effect 
Woo et al. [57] found that fucoxanthin significantly lowered the hepatic lipid contents, while feces 
weight and fecal lipids significantly increased by inhibiting lipid adsorption in high-fat diet fed 
C57BL/6N mice. Park et al. [85] also demonstrated that fucoxanthin significantly decreased the 
hepatic lipid droplet accumulation in high-fat fed mice, possibly through reducing the activity of 
hepatic fatty acid synthesis-related enzymes [57,85]. Furthermore, it was shown that there were no 
significant dose-dependent effects on hepatic lipid changes by 0.05% and 0.2% fucoxanthin and the 
0.05% fucoxanthin might be sufficient for improving the hepatic lipid content [57], while no 
significant change was found in the plasma lipids in Wister rats [86]. In addition, fucoxanthin Mar. Drugs 2011, 9  
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significantly up-regulated glycolytic enzyme such as glucokinase in the liver, and thus increased the 
ratio of hepatic glucokinase/glucose-6-phosphatase and glycogen content, indicating that fucoxanthin 
normalized the hepatic glycogen content in high-fat fed mice [85]. 
The reduction of liver lipids might be due to the increase of docosahexaenoic acid, which reduces 
the activity of hepatic enzymes in fatty acid synthesis and increases hepatic fatty acid β-oxidation, in 
the liver [86]. Tsukui et al. [97] first reported that fucoxanthin and fucoxanthinol enhanced the amount 
of docosahexaenoic acid in the liver of KK-Ay mice, whereas the level of docosahexaenoic acid in the 
small intestine remained unaltered. Subsequently, Tsukui et al. [43] confirmed that fucoxanthin 
increased the amount of docosahexaenoic acid in the liver of normal adult C57BL/6J mice. In addition, 
an increase in arachidonic acid (ω-6) was also found in fucoxanthin-fed mice, indicating that 
fucoxanthin might modify the metabolic pathways of ω-3 and ω-6 highly unsaturated fatty acids. 
Recently, Airanthi et al. [10] showed that the levels of docosahexaenoic acid and arachidonic acid in 
liver lipids of KK-Ay mice given the lipids from brown seaweeds significantly increased. 
Furthermore, Liu et al. [98] investigated the effects of fucoxanthin on hepatocyte lipid peroxidation 
and hepatotoxicity induced by ferric nitrilotriacetate in murine embryonic hepatic BNL CL.2 cells, and 
showed that fucoxanthin significantly recovered cell proliferation and increased the levels of 
glutathione. Moreover, fucoxanthin significantly decreased intracellular reactive oxygen species and 
DNA damage, and markedly decreased the level of thiobarbituric acid-reactive substances and protein 
carbonyl contents in BNL CL.2 cells induced by ferric nitrilotriacetate, indicating that fucoxanthin 
effectively protected against ferric nitrilotriacetate-induced hepatotoxicity by decreasing intracellular 
reactive oxygen species, thiobarbituric acid-reactive substances, and protein carbonyl contents, and 
increasing glutathione level, associated with the antioxidant effects of fucoxanthin. 
3.7. Skin-Protective Effect 
Over exposure to ultraviolet radiation from sunlight leading to the generation of reactive oxygen 
species, inflammatory reaction, and angiogenesis of the skin is presumed to be the primary causative 
agent in the damage of cellular constituents and some cutaneous disease such as pigmentation, laxity, 
wrinkling, erythema, and skin carcer [99,100]. Heo and Jeon [99] revealed that fucoxanthin 
significantly decreased intracellular reactive oxygen species generated by exposure to ultraviolet B 
radiation in human fibroblast. Fucoxanthin elevated cell survival rate and inhibited cell damage for 
pre-treated cells, indicating that fucoxanthin could protect skin against photodamage induced by 
ultraviolet B irradiation from sunlight. Shimoda et al. [101] found that fucoxanthin inhibited tyrosinase 
activity, melanogenesis in melanoma, and ultraviolet B-induced skin pigmentation. The results showed 
that fucoxanthin significantly suppressed expression of cyclooxygenase-2, endothelin receptor A, p75 
neurotrophin receptor, prostaglandin E receptor 1, melanocortin 1 receptor and tyrosinase-related 
protein 1, suggesting that fucoxanthin presented anti-pigmentary activity by topical or oral application 
in ultraviolet B-induced melanogenesis possibly through the suppression of prostaglandin E2 synthesis 
and melanogenic stimulant receptors. Recently, Urikura et al. [100] showed that fucoxanthin 
significantly suppressed ultraviolet B-induced epidermal hypertrophy,  which may cause wrinkle 
formation, vascular endothelial growth factor, matrix metalloproteinases-13 expression, and the 
increase of thiobarbituric acid reactive substances in the skin of hairless mice. The results indicated Mar. Drugs 2011, 9  
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that topical treatment with fucoxanthin prevented skin photoage and wrinkle formation in ultraviolet 
B-irradiated hairless mice, possibly through the antioxidant and antiangiogenic effects of fucoxanthin. 
These studies suggest that fucoxanthin may be an effective ultraviolet protcect ingredient able to be 
used in cosmetic and sunscreen in protecting skin from photoaging. Moreover, it would be worthy to 
probe into the effect of oral administration of fucoxanthin on skin photoage. 
3.8. Antiangiogenic Effect 
Sugawara et al. [93] investigated the antiangiogenic effects of fucoxanthin using cultured human 
umbilical vein endothelial cells and the rat aortic ring, and found that fucoxanthin could significantly 
suppress the differentiation of endothelial progenitor cells into endothelial cells and the formation of 
new blood vessels, and significantly reduced the tube length of endothelial cells. The results showed that 
fucoxanthin and fucoxanthinol inhibited microvessel outgrowth in an ex vivo angiogenesis assay using a 
rat aortic ring, suggesting that the antiangiogenic effect of fucoxanthin might be useful in preventing 
angiogenesis-related diseases, such as cancer, diabetic retinopathy, atherosclerosis and psoriasis. 
3.9. Cerebrovascular Protective Effect 
Ikeda  et al. [24] revealed that the brown seaweed U. pinnatifida significantly delayed the 
development of stroke signs with no change in blood pressure and increased the life span of salt-loaded 
hypertensive rats. In addition, the preventive effect of fucoxanthin on cultured neuronal cells from 
hypertensive rats was also investigated by Ikeda et al. [24], who found that fucoxanthin markedly 
attenuated neuronal cell injury in hypoxia and re-oxygenation, possibly through its radical-scavenging 
activity, and suggested that fucoxanthin had a beneficial effect on cerebrovascular diseases against 
ischaemic neuronal cell death in stroke-prone spontaneously hypertensive rats.  
3.10. Bone-Protective Effect 
Using cells from the macrophage cell line RAW264.7 able to differentiate into osteoclast-like cells 
when stimulated by receptor activator of nuclear factor κB ligand, Das et al. [41] investigated the effects 
of fucoxanthin on the osteoclast differentiation of precursor RAW264.7 monocytes and its cytotoxicity 
against the osteoclast-like cells differentiated from RAW264.7 cells and the osteoblast-like cell line 
MC3T3-E1 cells. The results showed that fucoxanthin significantly suppressed the differentiation of 
RAW264.7 cells with no toxicity to RAW264.7 cells, induced apoptosis through the activation of 
caspase-3 and sequentially the cleavage of poly-ADP-ribose polymerase in osteoclast-like cells, and 
did not decrease cell viability in the osteoblast-like cell line MC3T3-E1, indicating that the 
cytotoxicity of fucoxanthin against osteoclasts was stronger than that against osteoblasts. The study 
suggested that fucoxanthin suppressed osteoclastogenesis through inhibiting osteoclast differentiation 
and inducing apoptosis in osteoclasts, but did not antagonize bone formation, and fucoxanthinol might 
play an important role in inducing apoptosis in osteoclast-like cells and exert a suppressive effect on 
osteoclastogenesis. These results indicate that fucoxanthin is helpful for the prevention of bone 
diseases such as osteoporosis and rheumatoid arthritis. Mar. Drugs 2011, 9  
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3.11. Ocular Protective Effect 
After-cataract, also known as posterior capsule opacification, is the main long term complication  
of extracapsular cataract extraction due to the proliferation and migration of lens epithelial cells left in 
the capsular bag after cataract surgery [102]. The growth of human lens epithelial cell line SRA 01/04 
was apparently inhibited by fucoxanthin, indicating that fucoxanthin was an efficient and safe 
antiproliferative agent for human lens epithelial cell line and might be applied to the formulation of 
ocular implant products used in cataract treatment for the prevention of after-cataract [36]. 
In addition, Shiratori et al. [103] studied the anti-ocular inflammatory effect of fucoxanthin on 
lipopolysaccharide-induced uveitis in male Lewis rats, and found that fucoxanthin suppressed the 
development of the uveitis. 
3.12. Antimalarial Effect 
Malaria, widespread in tropical and subtropical regions, is a mosquito-borne infectious disease of 
humans caused by Plasmodium falciparum, a one-celled apicomplexan parasite. Afolayan et al. [21] 
first found that organic extract from brown seaweed S. heterophyllum exhibited promising 
antiplasmodial activity, and thus separated sargaquinoic acid, sargahydroquinoic acid, sargaquinal, and 
fucoxanthin from the extract for further investigation. The results indicated that fucoxanthin showed 
the highest antiplasmodial activity, while sargaquinal showed good antiplasmodial activity, and 
sargaquinoic acid and sargahydroquinoic acid were only moderately active. Although the 
antiplasmodial activities of four compounds might be related to their antioxidant properties, further 
studies were required in order to clarify their mode of action. 
4. Conclusions 
Growing evidence from tissue culture and animal experiment suggests that fucoxanthin has 
potential health promoting effects. Fucoxanthin has attracted considerable interest because of its potent 
bioactivities, including its antioxidant, anti-inflammatory, anticancer, anti-obese, antidiabetic, 
antiangiogenic, and antimalarial activities, and its protective effects on the liver, blood vessels of the 
brain, bones, skin, and eyes. Particularly, the anti-obese effect, antiproliferative effects on adult T-cell 
leukemia cells [53], and inhibitory effect on the viability of HL-60 cells [73] of fucoxanthin are 
distinctly more potent than that of β-carotene and astaxanthin. The unique suppressive effect of 
fucoxanthin on adipocyte differentiation is related to its structural properties, where an allenic bond is 
essential for the expression of this activity, and carotenoids without an allenic bond are not active [83]. 
Orally-administered fucoxanthin is metabolized into fucoxanthinol and amarouciaxanthin A in 
mice. Therefore, fucoxanthinol, amarouciaxanthin A, or other metabolites of fucoxanthin in human 
should be considered in mechanistic studies of the biological actions of fucoxanthin. Although some 
brown seaweeds containing high levels of fucoxanthin are the most common edible delicacies, some 
studies showed that the bioavailability of fucoxanthin in brown seaweeds was low in humans. 
However, dietary combination of fucoxanthin isolated from brown seaweeds or diatoms and edible oil 
or lipid could increase the absorption rate of fucoxanthin, and might be developed as a promising Mar. Drugs 2011, 9  
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marine drug. More extensive animal experimentation and well-controlled clinical trials are suggested 
for further studies. 
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